These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32770654)

  • 61. Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience.
    Burstein DS; Maude S; Grupp S; Griffis H; Rossano J; Lin K
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1590-1595. PubMed ID: 29772353
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The what, when and how of CAR T cell therapy for ALL.
    Frey N
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):275-281. PubMed ID: 29050700
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
    Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG
    J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia
.
    Callahan C; Baniewicz D; Ely B
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):22-28. PubMed ID: 28315553
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.
    Belin C; Devic P; Ayrignac X; Dos Santos A; Paix A; Sirven-Villaros L; Simard C; Lamure S; Gastinne T; Ursu R; Berger C; Platon L; Tessoulin B; Azoulay E; Wallet F; Thieblemont C; Bachy E; Cartron G; Laplaud DA; Carpentier AF
    Sci Rep; 2020 Nov; 10(1):18997. PubMed ID: 33149178
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
    Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
    Yurkiewicz I; Craig J; Muffly L
    Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL.
    Zhang Q; Hu H; Chen SY; Liu CJ; Hu FF; Yu J; Wu Y; Guo AY
    Genomics Proteomics Bioinformatics; 2019 Apr; 17(2):190-200. PubMed ID: 31201998
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities.
    Rubinstein JD; Nelson AS; Krupski C; O'Brien W; Taylor JM; Badgett TC; Huang M; Davies SM; Phillips CL
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28199. PubMed ID: 32020723
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
    Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
    J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety.
    Hao L; Li T; Chang LJ; Chen X
    Curr Med Chem; 2019; 26(17):3068-3079. PubMed ID: 28762313
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [CAR-T cells in acute lymphoblastic leukemias: What's new?].
    Grain A; Dourthe ME; Baruchel A
    Bull Cancer; 2020 Feb; 107(2):234-243. PubMed ID: 32035651
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
    Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chimeric antigen receptor T cell therapy can be administered safely under the real-time monitoring of Th1/Th2 cytokine pattern using the cytometric bead array technology for relapsed and refractory acute lymphoblastic leukemia in children.
    Shen D; Song H; Xu X; Xu W; Wang D; Liang J; Fang M; Liao C; Chen X; Li S; Zhao N; Huang W; Tang Y
    Pediatr Hematol Oncol; 2020 May; 37(4):288-299. PubMed ID: 32048885
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 79. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chimeric antigen receptor T-cell therapy for ALL.
    Maude SL; Shpall EJ; Grupp SA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.